CRP and chronic kidney disease: Patients with adverse events had higher age, higher prevalence of diabetes, chronic kidney disease, atrial fibrillation, ischemic cardiomyopathy etiology, ACE-Is or ARBs use, beta blockers use, diuretic use, statin use and intravenous inotropic use, higher brain natriuretic peptide, total bilirubin and CRP levels, and lower GNRI, heart rate, systolic blood pressure and eGFR, and lower hemoglobin, sodium, total cholesterol and albumin levels compared to those without adverse events (Tables 1 and 2).